Strona główna・Stock List・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Open

SectorHealthcare

258.52 9.88

Buy Sell

Overview

Share price change

24h

Current

Min

231.82

Max

263.86

Key metrics
By Trading Economics
Income	262M -15M
Sales	1.6M 996M
EPS	2.06
Profit margin	-1.486
Employees	18,300
EBITDA	-135M 64M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	-1.67% downside

Dividends
By Acuity
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	2.8B 11B
Previous open	248.64
Previous close	258.52

News Sentiment

By Acuity

10%

90%

14 / 340 Ranking in Healthcare

Charles River Laboratories International Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2026, 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

3 sie 2026, 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

31 lip 2026, 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30 lip 2026, 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29 lip 2026, 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

28 lip 2026, 18:02 UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

27 lip 2026, 17:36 UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

23 lip 2026, 00:01 UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

22 lip 2026, 22:01 UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

21 lip 2026, 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20 lip 2026, 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Peer Comparison

Price change

Charles River Laboratories International Inc Forecast

Price Target

By TipRanks

-1.67% downside

12 Months Forecast

Average 230.2 USD -1.67%

High 265 USD

Low 213 USD

Based on 12 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Charles River Laboratories International Inc - Dist in the past 3 months.

Sentiment

By Acuity

14 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.